Neuphoria Therapeutics (NEUP) Expected to Announce Quarterly Earnings on Friday

Neuphoria Therapeutics (NASDAQ:NEUP) is anticipated to issue its results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($4.41) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, analysts expect Neuphoria Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neuphoria Therapeutics Stock Down 0.2%

Shares of Neuphoria Therapeutics stock opened at $3.99 on Friday. Neuphoria Therapeutics has a 12 month low of $3.64 and a 12 month high of $21.40. The stock has a market cap of $21.47 million, a PE ratio of -0.82 and a beta of 0.52. The business has a fifty day simple moving average of $4.04 and a 200-day simple moving average of $7.48.

Analyst Ratings Changes

A number of brokerages recently commented on NEUP. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Wall Street Zen downgraded shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright lowered their target price on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, December 5th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $21.00.

Institutional Trading of Neuphoria Therapeutics

An institutional investor recently bought a new position in Neuphoria Therapeutics stock. Millennium Management LLC bought a new position in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 18,329 shares of the company’s stock, valued at approximately $216,000. Millennium Management LLC owned approximately 0.78% of Neuphoria Therapeutics at the end of the most recent reporting period. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.